Transluminal Technologies

Executive Summary

Transluminal Technologies is a privately held medical device company headquartered in Santa Rosa, California, dedicated to advancing interventional cardiology through minimally invasive solutions. Founded in 2015, the company focuses on developing novel devices that address unmet needs in the treatment of cardiovascular diseases, aiming to improve patient outcomes while reducing procedural complexity. Its core technology is designed to enhance precision and safety in catheter-based interventions, potentially expanding the treatable patient population and setting new standards in the field. Transluminal’s platform leverages proprietary delivery and deployment mechanisms that differentiate it from existing tools, offering the possibility of shorter recovery times and fewer complications. The company operates in the large and growing cardiovascular device market, where there is a strong demand for innovation that can lower healthcare costs and improve quality of life. With a seasoned management team and a clear focus on clinical validation, Transluminal is positioned to secure strategic partnerships and regulatory milestones that could rapidly accelerate its trajectory toward commercialization.

Upcoming Catalysts (preview)

• Q4 2026FDA Breakthrough Device Designation or 510(k) Clearance65% success
• Q2 2026Initial Clinical Trial Results for Lead Product55% success
• Q3 2026Series B or Strategic Partnership Funding Round70% success